

AKORN INC  
Form 8-K  
August 25, 2016

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): August 25, 2016

**Akorn, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Louisiana**

(State or Other Jurisdiction of  
Incorporation)

**001-32360**

(Commission File Number)

**72-0717400**

(I.R.S. Employer Identification  
Number)

**1925 W. Field Court, Suite 300 , Lake Forest, Illinois  
60045**

(Address of Principal Executive Offices) (Zip Code)

**(847) 279-6100**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On August 25, 2016, Akorn, Inc. announced its relaunching of Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated by reference into this Item 7.01.

The information in this Item 7.01, including exhibit 99.1 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. See attached exhibit index.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Akorn, Inc.**

Date: August 25, 2016

By: /s/ Duane A. Portwood  
Duane A. Portwood  
Chief Financial Officer

---

**Exhibit Index**

Exhibit Number	Description of Exhibit
99.1	Press release dated August 25, 2016, issued by Akorn, Inc. entitled “Akorn Relaunches Ofloxacin Otic Solution.”